Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioCryst Provides Updates On Peramivir For Influenza Patients
BioCryst Pharmaceuticals has delivered a written response to the request for proposal (RFP) announced on September 21, 2009 from the US Department of Health & Human Services (HHS)
BioCryst Pharmaceuticals has delivered a written response to the request for proposal (RFP) announced on September 21, 2009 from the US Department of Health & Human Services (HHS)
Sagent Pharmaceuticals has launched vinorelbine injection, USP, an anti-mitotic chemotherapy drug. Sagent will begin marketing and shipping vinorelbine injection immediately. Sagent’s vinorelbine injection is offered in 10mg per
Hana Biosciences has announced that the company has entered into a Clinical Trial Agreement (CTA) with the Center for Cancer Research (CCR) at the National Cancer Institute (NCI)
Welichem Biotech has announced the filing with Health Canada of a clinical trial application for its lead, anti-inflammatory drug WBI-1001. The application is for a 3-month, double blinded
Sanofi-Aventis has announced that ClikSTAR, a new reusable insulin pen, for administration of the 24-hour insulin analog Lantus (insulin glargine [rDNA] injection) or/and the rapid acting insulin analog
Can-Fite BioPharma has initiated the preparatory work for a phase III trial with CF101 in psoriasis. This is based on the conclusion of a phase II dose-response clinical
Palatin Technologies will receive $5m from AstraZeneca relating to an amendment of its ongoing exclusive research collaboration and license agreement to discover, develop and commercialise compounds that target
ATMI has expanded its line of Newsafe contained Powder Transfer Bags with the introduction of bags fabricated with a new anti-static polymer film that increases the number of
Sepha, a blister packing, deblistering, and pharmaceutical leak testing company, commented that the pressure to reduce waste is raising demands for its Press-Out deblistering technologies, quotes in-Pharma. The
Lupin has acquired US rights for Antara (Fenofibrate capsules 43mg, and 130mg) for $38.61m from Oscient Pharmaceuticals. Lupin had filed an ANDA for fenofibrate capsules 43mg and 130mg.